Crossref
Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer
Current Oncology · 2012
DOI: 10.3747//co.19.959 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2012. Verfasst von V. Hirsh.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Hirsh, V. (2012). Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer. Current Oncology. https://doi.org/10.3747//co.19.959
Vancouver
Hirsh V. Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer. Current Oncology. 2012. doi:10.3747//co.19.959
BibTeX
@article{Hirsh2012,
author = {Hirsh, V.},
title = {Second-line erlotinib in an EGFR mutation-negative patient with non-small-cell lung cancer},
journal = {Current Oncology},
year = {2012},
doi = {10.3747//co.19.959}
}
EUVIMED